论文部分内容阅读
高原肺动脉高压发病机制是低压缺氧引起肺血管重构,肺动脉中膜增厚,肺血管阻力增加,从而导致肺动脉压升高和右心室衰竭。肺血管重构是高原肺动脉高压的基本病理学特征。多数研究认为,阻遏或逆转肺血管重构应成为治疗肺高压的靶标。本文通过对他汀类药物治疗肺高压的研究进展做一综述,认为他汀类药物应用于临床治疗高原肺动脉高压前景广阔。
The pathogenesis of high altitude pulmonary hypertension is hypobaric hypoxia caused by pulmonary vascular remodeling, pulmonary intimal thickening, pulmonary vascular resistance increased, leading to pulmonary hypertension and right ventricular failure. Pulmonary vascular remodeling is the basic pathological features of plateau pulmonary hypertension. Most studies suggest that repressing or reversing pulmonary vascular remodeling should be the target of treatment for pulmonary hypertension. This review summarizes the research progress of statins in the treatment of pulmonary hypertension, and holds the view that statins have a bright prospect in clinical treatment of pulmonary hypertension in the highlands.